A5415: A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV

HIV (and comorbidities)

The purpose of this study is to see if cenicriviroc mesylate (or CVC) can reduce inflammation of the arteries (the blood vessels that carry blood from the heart through the body) in people living with HIV (human immunodeficiency virus) (the virus that causes acquired immune deficiency syndrome [AIDS]). This study will also look at how safe CVC is when it is taken by people living with HIV who are taking anti-HIV medications.

24 weeks